LIST OF US PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS GRANTED IN 2011
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included pharmaceutical
formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release; polysaccharides,
polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular or buccal
administration of medications and related subjects.
US Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Granted in 2011
Clck to enlarge and view details
US Patents Granted in 2012
US Patents Granted in 2010
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION GRANTED IN 2011



Patent No.: US7867517B2  Issued: 11/Jan/2011

Title: Oral pharmaceutical composition with improved bioavailability

Applicant/Assignee: FARMATRON, LTD

Application No.: 10/482460   Filing Date: 23/Jul/2004

Abstract:

The present invention relates to prompt-release oral pharmaceutical compositions containing one or more active principles solubilised, suspended or embedded in a suitably formulated amphiphilic matrix for improving in vitro and in vivo bioavailability of medicaments sparingly absorbed through the oral route and/or with problems of high variability of absorption in the gastrointestinal tract.

Priority: WO2002EP06748 Applic. Date: 2002-06-19; IT2001MI01338 Applic. Date: 2001-06-26

Inventor: MASSIRONI MARIA GABRIELLA [GB]


Patent No.: US7867545B2  Issued: 11/Jan/2011

Title: Homogenous granular solid matrix containing vegetable protein

Applicant/Assignee: J.P.M.E.D. LTD

Application No.: 11/685124   Filing Date: 12/Mar/2007

Abstract:

The present invention relates to a homogeneous solid matrix composition containing vegetable proteins, lecithin and at least one ingestible bioactive compound which is at least partially insoluble in an aqueous medium.

Priority: IL20000134701 Applic. Date: 2000-02-23; US2002-203178 Applic. Date: 2002-08-05; WO2001IL00128 Applic. Date: 2001-02-08

Inventor: FRIEDMAN DORON I [IL]


Patent No.: US7867611B2  Issued: 11/Jan/2011

Title: BIOMEDICAL SENSORS EMPLOYING HYDRO-INSENSITIVE ALTERNATING CURRENT RESPONSIVE COMPOSITES

Applicant/Assignee: FLEXCON COMPANY, INC

Application No.: 12/751558   Filing Date: 31/Mar/2010

Abstract:

A biomedical sensor is disclosed that includes a conductive material for coupling to monitoring equipment, and a composite. The composite includes a polymeric material and a polar material that is substantially dispersed within the polymeric material. The composite has a first side that is coupled to the conductive material and has a second side that is positionable with respect to a subject to be monitored. The polar material exhibits molecular compatibility with the polymeric material such that the polar material neither blooms to a surface of the polymeric material nor crystallizes within the polymeric material.

Priority: US2008-123773 Applic. Date: 2008-05-20; US2003-410988 Applic. Date: 2003-04-10; US20020371306P Applic. Date: 2002-04-10

Inventor: SEGALL DANIEL P [US]; HILTON IRIS E [US]; SZYMANSKI MELISSA E [US]; PENNACE JOHN R [US]


Patent No.: US7871645B2  Issued: 18/Jan/2011

Title: Ion Exchange Resin Treated to Control Swelling

Applicant/Assignee: COATING PLACE, INC

Application No.: 11/674921   Filing Date: 14/Feb/2007

Abstract:

The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the solution to load more drugs onto the drug-loaded resin particle from the solution.

Priority: US2005-225834 Applic. Date: 2005-09-13

Inventor: HALL HARLAN [US]; MADSEN J SCOTT [US]


Patent No.: US7875212B2  Issued: 25/Jan/2011

Title: POLYMER MATRIX COMPOSITES WITH NANO-SCALE REINFORCEMENTS

Applicant/Assignee: UNIVERSITY OF HAWAII

Application No.: 12/703136   Filing Date: 09/Feb/2010

Abstract:

Embodiments of the present invention provide polymer matrix nanocomposites reinforced with nano-scale materials such as nanoparticles and carbon nanotubes and methods of fabricating. The nanomaterials are provided within relatively low weight fractions, for example in the range of approximately 0.01 to about 0.4% by weight and distributed within the matrix by a magnetic mixing procedure to provide substantially uniform reinforcement of the nanocomposites. Advantageously, these nanocomposites provide significantly enhanced tensile strength, strain to failure, and fracture toughness over corresponding neat matrices.

Priority: US2006-524091 Applic. Date: 2006-09-20; US20050753006P Applic. Date: 2005-12-21; US20050753155P Applic. Date: 2005-12-20; US20050753496P Applic. Date: 2005-12-22

Inventor: NEJHAD MOHAMMAD NAGHI GHASEMI [US]; VEEDU VINOD P [US]; YUEN ANDREA [US]; ASKARI DAVOOD [US]


Patent No.: US7875294B2  Issued: 25/Jan/2011

Title: Method of attenuating bruise formation

Applicant/Assignee: FERRIS PHARMACEUTICALS, INC, SESSIONS PHARMACEUTICALS INC

Application No.: 11/528780   Filing Date: 28/Sep/2006

Abstract:

The present invention provides a method of attenuating the formation or reducing the severity of a bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of bruising.

Priority: US2006-440550 Applic. Date: 2006-05-25; US2002-175119 Applic. Date: 2002-06-19; US2001-789275 Applic. Date: 2001-02-20; US1999-326836 Applic. Date: 1999-06-07; US19980088424P Applic. Date: 1998-06-08

Inventor: SESSIONS ROBERT W [US]; KAHN ALAN R [US]


Patent No.: US7879333B2  Issued: 01/Feb/2011

Title: Methods for preparing and delivering adjuvant compositions

Applicant/Assignee: ADVANCED BIOADJUVANTS, LLC

Application No.: 10/792725   Filing Date: 05/Mar/2004

Abstract:

Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based. The method of preparation includes hydrating lecithin and a polymer in saline or water and mixing the lecithin and polymer to form the adjuvant.

Priority: US2003-426654 Applic. Date: 2003-05-01; US2001-884201 Applic. Date: 2001-06-19

Inventor: GERBER JAY D [US]


Patent No.: US7879353B2  Issued: 01/Feb/2011

Title: Controlled or sustained-release formulation

Applicant/Assignee: ETHICON, INC

Application No.: 11/110967   Filing Date: 20/Apr/2005

Abstract:

A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide

wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, and the co-polyester comprises about 40% by weight of the polycondensation polyester based on the total weight of the co-polyester

and a drug selected from the group consisting of indomethacin, diclofenac sodium, and ketoprofen.

Priority:

Inventor: YUAN JENNY [US]; ANDJELIC SASA [US]


Patent No.: US7887842B2  Issued: 15/Feb/2011

Title: Methods of administering a dermatological agent to a subject

Applicant/Assignee: TEIKOKU PHARMA USA, INC, TEIKOKU SEIYAKU KABUSHIKI KAISHA

Application No.: 10/754477   Filing Date: 08/Jan/2004

Abstract:

Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

Priority: US20030445572P Applic. Date: 2003-02-07

Inventor: KOO JOHN [US]; SHUDO JUTARO [US]; SHIRAI SADANOBU [JP]


Patent No.: US7887845B2  Issued: 15/Feb/2011

Title: Antiviral compositions

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: 11/347071   Filing Date: 03/Feb/2006

Abstract:

The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.

Priority: EP19990203128 Applic. Date: 1999-09-24; US2002-088805 Applic. Date: 2002-03-21; WO2000EP08522 Applic. Date: 2000-08-31

Inventor: VERRECK GEERT [BE]; BAERT LIEVEN [BE]


Patent No.: US7897174B2  Issued: 01/Mar/2011

Title: Formulation comprising bioactive agents and method of using same

Applicant/Assignee: UNIVERSITY OF ERLANGEN-NURNBERG, WYETH INC

Application No.: 10/361263   Filing Date: 10/Feb/2003

Abstract:

Disclosed are methods of making BMP-2 microparticles and methods of using the microparticles. These microparticles are prepared, for example, by mixing a solution containing BMP-2 with a second solution whose ionic concentration and pH results in the precipitation of the BMP-2.

Priority: US20020355135P Applic. Date: 2002-02-08

Inventor: SOFIA SUSAN J [US]; SCHWARTZ DANIEL [DE]; FRIESS WOLFGANG [DE]


Patent No.: US7897175B2  Issued: 01/Mar/2011

Title: Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor

Applicant/Assignee: PFIZER INC, BEND RESEARCH, INC

Application No.: 10/739567   Filing Date: 18/Dec/2003

Abstract:

A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.

Priority: US20020435345P Applic. Date: 2002-12-20

Inventor: FRIESEN DWAYNE T [US]; LYON DAVID K [US]; LORENZ DOUGLAS A [US]; HANCOCK BRUNO C [US]; MCDERMOTT TIMOTHY J [US]; SHANKER RAVI M [US]


Patent No.: US7897563B2  Issued: 01/Mar/2011

Title: USE OF OLIGOMERS AND POLYMERS FOR DRUG SOLUBILIZATION, STABILIZATION, AND DELIVERY

Applicant/Assignee: SOANE FAMILY TRUST

Application No.: 12/337991   Filing Date: 18/Dec/2008

Abstract:

The invention relates to the use of oligomers and polymers capable of rendering insoluble drugs soluble, protecting unstable drugs, and facilitating the delivery of drugs to their site of action. This invention further relates to processes for the preparation of such oligomers and polymers, and to compositions containing them. In some instances, oligomers, polymers, and/or mixtures thereof can be used to protect a protein drug. Such structures can include at least one recognition element covalently attached to a hydrophilic element, wherein said recognition element or elements interact noncovalently with the protein drug to form a complex in which said protein drug is protected from degradation, recognition by the immune system, and/or renal excretion.

Priority: US2002-328898 Applic. Date: 2002-12-23; US20010343483P Applic. Date: 2001-12-21

Inventor: SOANE DAVID S [US]; SUICH DANIEL J [US]


Patent No.: US7901606B2  Issued: 08/Mar/2011

Title: Production of Porous Materials by Supercritical Fluid Processing

Applicant/Assignee: FERRO CORPORATION

Application No.: 10/552008   Filing Date: 21/Jun/2005

Abstract:

The present invention provides a method of producing porous structures, particles or matrixes, which may be comprised of one or a plurality of components, an apparatus for carrying out the method and particles formed in accordance with the method. The method is particularly suitable for producing porous composite or pure particles for pharmaceutical applications. In accordance with the method, a composite comprising a material such as a pharmaceutical, a biodegradable polymers and/or a biological agent is formed. The composite must further comprise a material that is soluble in supercritical fluid. Extraction of the supercritical fluid soluble material produces porous structures, which may be in the form of particles or matrixes.

Priority: US20040587303P Applic. Date: 2004-07-12; WO2005US21970 Applic. Date: 2005-06-21

Inventor: CHATTOPADHYAY PRATIBHASH [US]; SHEKUNOV BORIS Y [US]; SEITZINGER JEFFREY S [US]


Patent No.: US7906142B2  Issued: 15/Mar/2011

Title: Agropolymer material for use in water purification and a method of producing the same

Applicant/Assignee: BIJAM BIOSCIENCES PRIVATE LIMITED

Application No.: 11/142939   Filing Date: 02/Jun/2005

Abstract:

The present invention relates to novel agropolymers, which comprise a carbohydrate and/or silica matrix substantially devoid of proteins, tannins and polyphenols and which comprise metal binding reactive sites. A method of producing the agropolymers is also disclosed wherein the agropolymers are derived from plant materials such as seed coats, seed covers, husks, or hulls of various agricultural crops. The agricultural crops typically used to produce the agropolymers include Oryza sativa, Panicum miliaceum, Setaria italica, Cajanus cajan, Vigna mungo, Vigna radiata, Triticum sp., Ricinus communis, Helianthus annus, Gossypium sp., and Arachis sp. The agropolymers of the present invention are capable of purifying aqueous solutions polluted or contaminated with metals and/or ions.

Thus, the present invention also discloses a method whereby agropolymers are used in the purification of contaminated water and other aqueous solutions. The agropolymers disclosed herein are useful in several industrial applications including purifying polluted drinking water or ground water.

Priority: IN1999MA00222 Applic. Date: 1999-02-24; IN1999MA00223 Applic. Date: 1999-02-24; US2001-938757 Applic. Date: 2001-08-24; WO2000IN00015 Applic. Date: 2000-02-24

Inventor: PRASAD YANDAPALLI DURGA [IN]


Patent No.: US7906151B2  Issued: 15/Mar/2011

Title: Cosmetic preparation containing a stabilized preservative

Applicant/Assignee: BEIERSDORF AG

Application No.: 10/864480   Filing Date: 10/Jun/2004

Abstract:

Cosmetic or dermatological composition comprising potassium sorbate and at least one stabilizing agent selected from microcrystalline cellulose, talc and a lipid having an interfacial tension of at least about 10 mN/m.

Priority: DE20031026899 Applic. Date: 2003-06-14

Inventor: KROEPKE RAINER [DE]; HEPTNER ASTRID [DE]; VON DER FECHT STEPHANIE [DE]; NIELSEN JENS [DE]; STORBECK CELINA [DE]


Patent No.: US7914805B2  Issued: 29/Mar/2011

Title: Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/632054   Filing Date: 31/Jul/2003

Abstract:

An implantable or insertable medical device which comprises (a) a therapeutic agent and (b) a polymeric release region comprising a polymer. The polymeric release region is treated with a radiation dose that is effective to substantially increase the cumulative release of the therapeutic agent subsequent to administration to a patient. The polymeric release region can be, for example, (a) a carrier region that comprises the therapeutic agent or (b) a barrier region that is disposed over a therapeutic-agent-containing region that comprises the therapeutic agent. The present invention is further directed to methods of forming such medical devices, methods of releasing a therapeutic agent within a patient using such medical devices, and methods of modulating the release of a therapeutic agent from such medical devices.

Priority:

Inventor: RICHARD ROBERT E [US]; SCHWARZ MARLENE C [US]


Patent No.: US7918897B2  Issued: 05/Apr/2011

Title: Scaffolds for organ reconstruction and augmentation

Applicant/Assignee: TENGION, INC

Application No.: 11/706081   Filing Date: 12/Feb/2007

Abstract:

Biocompatible synthetic or natural scaffolds are provided for the reconstruction, repair, augmentation or replacement of organs or tissue structures in a patient in need of such treatment. The scaffolds are shaped to conform to at least a part of the organ or tissue structure and may be seeded with one or more cell populations. Inserts, receptacles and ports are also provided for the attachment of tubular vessels to the neo-organ scaffolds. The seeded scaffolds are implanted into the patient at the site in need of treatment to form an organized organ or tissue structure. The scaffolds may be used to form organs or tissues, such as bladders, urethras, valves, and blood vessels.

Priority: US20060772754P Applic. Date: 2006-02-10

Inventor: BERTRAM TIMOTHY A [US]; BRUCE ANDREW [US]; JAIN DEEPAK [US]; JAYO MANUEL J [US]; LUDLOW JOHN W [US]; MCCOY DARELL [US]; PAYNE RICHARD [US]; SANGHA NAMRATA D [US]


Patent No.: US7919109B2  Issued: 05/Apr/2011

Title: Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Applicant/Assignee: INTARCIA THERAPEUTICS, INC

Application No.: 12/075435   Filing Date: 11/Mar/2008

Abstract:

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 110-7 reciprocal second.

Priority: US2000-627531 Applic. Date: 2000-07-28; US2000-497422 Applic. Date: 2000-02-03; US19990119170P Applic. Date: 1999-02-08

Inventor: BERRY STEPHEN A [US]; FEREIRA PAMELA J [US]; DEHNAD HOUDIN [US]; MUCHNIK ANNA [US]


Patent No.: US7919117B2  Issued: 05/Apr/2011

Title: TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN

Applicant/Assignee: SCHWARZ PHARMA AG, UCB PHARMA GMBH

Application No.: 12/417405   Filing Date: 02/Apr/2009

Abstract:

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.

Priority: DE20031015878 Applic. Date: 2003-04-08; US2005-533683 Applic. Date: 2005-04-26; WO2004EP03574 Applic. Date: 2004-04-03

Inventor: BREITENBACH ARMIN [DE]; MEESE CLAUS [DE]; WOLFF HANS-MICHAEL [DE]; DREWS ROLAND [DE]


Patent No.: US7919119B2  Issued: 05/Apr/2011

Title: Porous drug matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE INC, ACUSPHERE, INC

Application No.: 10/053929   Filing Date: 22/Jan/2002

Abstract:

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug.

Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Priority: US1999-433486 Applic. Date: 1999-11-04; US19990136323P Applic. Date: 1999-05-27; US19990158659P Applic. Date: 1999-10-08

Inventor: STRAUB JULIE [US]; ALTREUTER DAVID [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KHATTAK SARWAT [US]; RANDALL GREG [US]


Patent No.: US7923026B2  Issued: 12/Apr/2011

Title: EMBEDDED MICELLAR NANOPARTICLES

Applicant/Assignee: SOLVAY PHARMACEUTICALS B.V

Application No.: 11/875328   Filing Date: 19/Oct/2007

Abstract:

The present invention relates to a thermostable solid composition containing nanosized micelles, the micelles containing a poorly soluble chemical substance, such as a biologically active substance, dissolved in an auxiliary material, and the micelles being embedded in a water soluble carrier. The invention further relates to a process for preparing a thermostable solid composition and to a process for preparing pharmaceutical dosage forms comprising the same.

Priority: US20060853023P Applic. Date: 2006-10-20

Inventor: MOESCHWITZER JAN PETER [NL]


Patent No.: US7923035B2  Issued: 12/Apr/2011

Title: Humidity-dependent antibacterial powdery composition, process for producing the same, humidity-dependent antibacterial food storing article and method of storing food

Applicant/Assignee: MITSUBISHI-KAGABU FOODS CORPORATION, MITSUBISHI-KAGAKU FOODS CORPORATION

Application No.: 10/532077   Filing Date: 21/Apr/2005

Abstract:

The humidity-dependent antibacterial powdery composition comprises a volatile oily antibacterial substance contained in a high ratio and a water-soluble film forming agent and the behavior of release of the antibacterial substance is changed depending on humidity. The process for producing the same is characterized in that a water-soluble film forming agent optionally together with a powder vehicle is dissolved and/or dispersed in water, subsequently a volatile oily antibacterial substance optionally together with an emulsifying agent is added to the solution and emulsified, and thereafter the obtained emulsion is spray dried into powder. The humidity-dependent antibacterial food storing article is characterized by carrying the humidity-dependent antibacterial powdery composition.

The method of storing food is characterized in that the volatile oily antibacterial substance is released from the humidity-dependent antibacterial food storing article toward food lying in an atmosphere of 70% or higher humidity.

Priority: JP20020311677 Applic. Date: 2002-10-25; WO2003JP13469 Applic. Date: 2003-10-22

Inventor: II SHIGEO [JP]; TAKATA ASAMI [JP]; MIZUKAMI YUICHI [JP]; YASHIKI IKUO [JP]


Patent No.: US7932258B2  Issued: 26/Apr/2011

Title: Use of a partially neutralized, anionic (meth) acrylate copolymer as a coating for the production of a medicament pharmaceutical form releasing active substance at reduced pH values

Applicant/Assignee: EVONIK ROEHM GMBH

Application No.: 11/994440   Filing Date: 05/Apr/2006

Abstract:

The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group, at least 4 percent of which are neutralized by means of a base, for producing a medicament that is provided with an active substance-containing core and is coated with the partially neutralized, anionic (meth)acrylate copolymer. The medicament releases at least 30 percent of the active substance contained therein in 30 minutes at a pH at which the active substance is sufficiently soluble and stable and at which the corresponding medicament that is coated with the non-neutralized anionic (meth)acrylate polymer releases less than 10 percent of the active substance contained therein.

Priority: DE200510032806 Applic. Date: 2005-07-12; WO2006EP03115 Applic. Date: 2006-04-05

Inventor: PETEREIT HANS-ULRICH [DE]; ASSMUS MANFRED [DE]


Patent No.: US7935682B2  Issued: 03/May/2011

Title: Wound healing dressing for enhancing fibrocyte formation

Applicant/Assignee: WILLIAM MARSH RICE UNIVERSITY

Application No.: 11/158723   Filing Date: 22/Dec/2003

Abstract:

The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.

Priority: WO2003US41183 Applic. Date: 2003-12-22; US20020436046P Applic. Date: 2002-12-23; US20020436027P Applic. Date: 2002-12-23; US20030515776P Applic. Date: 2003-10-30; US20030519467P Applic. Date: 2003-11-12; US20030525175P Applic. Date: 2003-11-26

Inventor: GOMER RICHARD [US]; PILLING DARRELL [US]


Patent No.: US7943170B2  Issued: 17/May/2011

Title: Sustained release paracetamol containing compositions

Applicant/Assignee: SMITHKLINE BEECHAM LIMITED

Application No.: 10/257077   Filing Date: 06/Jun/2003

Abstract:

A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.

Priority: WO2001EP04302 Applic. Date: 2001-04-12; GB20000009522 Applic. Date: 2000-04-19

Inventor: CHAN SHING YUE [US]; GRATTAN TIMOTHY JAMES [AU]; SENGMANEE BOUNKHIENE [AU]


Patent No.: US7943173B2  Issued: 17/May/2011

Title: Pharmaceutical combinations of oxycodone and naloxone

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 10/199972   Filing Date: 18/Jul/2002

Abstract:

Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof.

Priority: US20010306301P Applic. Date: 2001-07-18

Inventor: BREDER CHRISTOPHER D [US]; COLUCCI ROBERT D [US]; HOWARD STEPHEN A [US]; OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]


Patent No.: US7943174B2  Issued: 17/May/2011

Title: Controlled release hydrocodone formulations

Applicant/Assignee: EURO-CELTIQUE, S.A, PURDUE PHARMA L.P

Application No.: 10/864829   Filing Date: 09/Jun/2004

Abstract:

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Priority: US2000-702283 Applic. Date: 2000-10-30; US19990162541P Applic. Date: 1999-10-29

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN [US]; TONELLI ALFRED P [US]


Patent No.: US7943175B2  Issued: 17/May/2011

Title: Calixarene based dispersible colloidal systems in the form of nanoparticles

Applicant/Assignee: NANOPORT S.A

Application No.: 10/489894   Filing Date: 17/Mar/2004

Abstract:

A water dispersible colloidal system in the form of generally spherical matrix type particles and of sizes typically in the range of from 50 to 500 nm, called nanoparticles, and a process for the preparation of such systems. The system is characterized in that the nanoparticles comprise at least one amphiphilically modified calixarene. The water dispersion contains at least one active component such as a cosmetic, a pharmaceutical compound or other biologically active substances, foods, beverages, etc. enclosed within the nanoparticles, in the outer aqueous phase, or in both. The systems show outstanding properties, especially long-life stability even at elevated la temperatures.

Priority: EP20010122184 Applic. Date: 2001-09-17; WO2002EP10169 Applic. Date: 2002-09-11

Inventor: COLEMAN ANTHONY [FR]; GORELOFF PHILIPPE JEAN-BORIS [FR]


Patent No.: US7943559B2  Issued: 17/May/2011

Title: CYCLOPROPANATED MACROCYCLIC KETONES AND LACTONES

Applicant/Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC

Application No.: 12/329091   Filing Date: 05/Dec/2008

Abstract:

The present invention is directed to novel cyclopropanated macrocyclic ketone and lactone compounds of the general formula: wherein X is an atom or a functional group selected from the group consisting of O, N, S, R-CH, and CH2

wherein R is a C1-C3 alkyl group

wherein Y and W independently represent is a linear or branched alkyl or alkenyl group, optionally substituted, consisting of less than 10 and preferably less than 7 carbon atoms

and wherein O is an oxygen atom, and the use of these novel compounds in creating fragrances and scents in items such as perfumes, colognes, and personal care products.

Priority: US2007-674523 Applic. Date: 2007-02-13; US2006-386957 Applic. Date: 2006-03-22; US2005-105626 Applic. Date: 2005-04-14

Inventor: NARULA ANUBHAV P S [US]; ARRUDA EDWARD MARK [US]; SCHIET FRANC T [NL]


Patent No.: US7947306B2  Issued: 24/May/2011

Title: MODIFICATIONS OF SOLID 3-SN-PHOSPHOGLYCERIDES

Applicant/Assignee: BIOMOLECULAR PRODUCTS, INC

Application No.: 12/142370   Filing Date: 19/Jun/2008

Abstract:

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Priority: US2004-492252 Applic. Date: 2004-08-05; WO2002US32647 Applic. Date: 2002-10-11; US20010328660P Applic. Date: 2001-10-11

Inventor: YESAIR DAVID W [US]; SHAW WALTER A [US]; BURGESS STEPHEN W [US]; MCKEE ROBERT TRAVIS [US]


Patent No.: US7951393B2  Issued: 31/May/2011

Title: Keloid Therapy

Applicant/Assignee:

Application No.: 12/268754   Filing Date: 11/Nov/2008

Abstract:

Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keloid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited.

Priority: US20070987800P Applic. Date: 2007-11-14

Inventor: HARRIS CANAAN VERNON LAVELLE [US]


Patent No.: US7951398B2  Issued: 31/May/2011

Title: Pharmaceutical preparation comprising an active dispersed on a matrix

Applicant/Assignee: ALTANA PHARMA AG, NYCOMED GMBH

Application No.: 11/642621   Filing Date: 21/Dec/2006

Abstract:

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Priority: EP20000126847 Applic. Date: 2000-12-07; US2003-433398 Applic. Date: 2003-09-11; WO2001EP14307 Applic. Date: 2001-12-06

Inventor: DIETRICH RANGO [DE]; LINDER RUDOLF [DE]; NEY HARTMUT [DE]


Patent No.: US7951401B2  Issued: 31/May/2011

Title: Stabilised solid drug dispersions in an organic carrier and a process for preparing the same

Applicant/Assignee: EURAND S.P.A

Application No.: 10/540139   Filing Date: 22/Dec/2003

Abstract:

New solid drug dispersions are described in which a drug is present in amorphous form and dispersed within the particles of an organic carrier selected from cross-linked polymers and/or complexing agents. These dispersions are obtainable by mixing the drug and the carrier and applying an oscillating electromagnetic field in the microwave region according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes.

Priority: IT2002MI02748 Applic. Date: 2002-12-23; WO2003EP14740 Applic. Date: 2003-12-22

Inventor: COLOMBO ITALO [IT]; GERVASONI DARIO [IT]


Patent No.: US7951846B2  Issued: 31/May/2011

Title: PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Application No.: 12/435283   Filing Date: 04/May/2009

Abstract:

Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.

Priority: US2004-846487 Applic. Date: 2004-05-14; US2003-640739 Applic. Date: 2003-05-19; US20020381970P Applic. Date: 2002-05-19

Inventor: BAE YOU HAN [US]; NA KUN [US]; LEE EUN SEONG [US]


Patent No.: US7959946B2  Issued: 14/Jun/2011

Title: Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Applicant/Assignee: WATSON PHARMACEUTICALS, INC

Application No.: 10/777542   Filing Date: 12/Feb/2004

Abstract:

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Priority: US2003-664803 Applic. Date: 2003-09-19; US20020412180P Applic. Date: 2002-09-20; US20020412181P Applic. Date: 2002-09-20

Inventor: KOSITPRAPA UNCHALEE [US]; GOLDFARB ROBERT I [US]; CARDINAL JOHN R [US]; NANGIA AVINASH [US]


Patent No.: US7964202B2  Issued: 21/Jun/2011

Title: Method for treatment of common acne

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, S.N.C

Application No.: 12/076859   Filing Date: 24/Mar/2008

Abstract:

Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4 DEG C. to 40 DEG C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress [tau] for a given rate gradient [gamma] and which measure a rate gradient [gamma] for a given shear stress [tau], the yield value ([tau]0) being extrapolated visually or by calculation.

Priority: FR20010016747 Applic. Date: 2001-12-21; US2002-326389 Applic. Date: 2002-12-23; US20020351382P Applic. Date: 2002-01-28

Inventor: ORSONI SANDRINE [FR]; WILLCOX NATHALIE [FR]


Patent No.: US7964210B2  Issued: 21/Jun/2011

Title: Degradable polymeric implantable medical devices with a continuous phase and discrete phase

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 11/395048   Filing Date: 31/Mar/2006

Abstract:

The invention provides an implantable medical device comprising: a structural element, wherein the structural element includes: a continuous phase comprising a first polymer

a discrete phase within the continuous phase, wherein the discrete phase has a second polymer including discrete phase segments

and anchor segments that have substantially the same chemical make up as the first polymer of the continuous phase

wherein at least some of the anchor segments have partially or completely phase-separated from the discrete phase into the continuous phase.

Priority:

Inventor: WANG YUNBING [US]; GALE DAVID C [US]; HUANG BIN [US]; HOSSAINY SYED F A [US]; GUERIGUIAN VINCENT J [US]


Patent No.: US7968107B2  Issued: 28/Jun/2011

Title: Oil-Based Suspension Concentrates

Applicant/Assignee: BAYER CROPSCIENCE AG

Application No.: 10/591129   Filing Date: 04/Mar/2005

Abstract:

New, oil-based suspension concentrates composed of at least one room-temperature-solid active agrochemical substance, at least one "closed" penetrant, at least one vegetable oil or mineral oil, at least one nonionic surfactant and/or at least one anionic surfactant, and optionally one or more additives from the groups of the emulsifiers, foam inhibitors, preservatives, antioxidants, colorants and/or inert filler materials, a process for producing these suspension concentrates and their use for applying the active substances comprised.

Priority: DE200410011007 Applic. Date: 2004-03-06; WO2005EP02285 Applic. Date: 2005-03-04

Inventor: BAUR PETER [DE]; FISCHER REINER [DE]; VERMEER RONALD [DE]


Patent No.: US7968122B2  Issued: 28/Jun/2011

Title: Anti-viral pharmaceutical compositions

Applicant/Assignee: SD PHARMACEUTICALS, INC, ADVENTRX PHARMACEUTICALS, INC

Application No.: 11/003302   Filing Date: 03/Dec/2004

Abstract:

The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.

Priority: US20030528843P Applic. Date: 2003-12-10

Inventor: CHEN ANDREW XIAN [US]


Patent No.: US7972589B2  Issued: 05/Jul/2011

Title: Hair fixative film

Applicant/Assignee: AKZO NOBEL N.V

Application No.: 10/847081   Filing Date: 17/May/2004

Abstract:

The present invention relates to a hair fixative film, which contains a natural and/or synthetic polymer as the main component and a method of applying said film to hair. Such film is useful in maintaining a desired look and style of hair. Furthermore, the film is beneficial because it enables the combination of ingredients that are incompatible in other application forms.

Priority:

Inventor: LEIGHTON JOHN C [US]; PHILBIN MICHAEL T [US]


Patent No.: US7973085B2  Issued: 05/Jul/2011

Title: Gel Composition

Applicant/Assignee: SHISEIDO COMPANY LTD

Application No.: 12/304173   Filing Date: 06/Jun/2007

Abstract:

A gel composition having the formula R1O-[(AO)k(EO)m(AO)n]-R2 comprises (a) 0.1 to 60 mass % of a block-type alkylene oxide derivative, (b) an oil, and (c) 0.1 to 10 mass % of water. AO represents a C3-C4 oxyalkylene group

EO represents an oxyethylene group

k and n represent average addition mole numbers of the oxyalkylene group and m represents average addition mole number of the oxyethylene group, 1!<=m!<=70 and 1!<=k+n!<=70. The oxyethylene group is 20 to 80 mass % with respect to the sum of the oxyalkylene group (AO) and the oxyethylene group. R1 and R2 may be identical to or different from one another and are each a C1-C4 hydrocarbon group or a hydrogen atom. The composition has a continuous phase comprising the oil

and the viscosity of the composition at 25 DEG C. is 500 mPas or more.

Priority: JP20060162028 Applic. Date: 2006-06-12; JP20070011982 Applic. Date: 2007-01-22; WO2007JP61420 Applic. Date: 2007-06-06

Inventor: ISHIKUBO AKIRA [JP]; OHMORI TAKASHI [JP]; SUZUKI YUKI [JP]


Patent No.: US7973154B2  Issued: 05/Jul/2011

Title: Kits for diagnosis and monitoring of viral infection by analysis of viral transrenal nucleic acids in urine

Applicant/Assignee: TROVAGENE, INC

Application No.: 11/137935   Filing Date: 25/May/2005

Abstract:

The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.

Priority: IT2005RM00067 Applic. Date: 2005-02-17

Inventor: MELKONYAN HOVSEP [US]; CANNAS ANGELA [IT]; TOMEI LOUIS DAVID [IT]; UMANSKY SAMUIL R [US]


Patent No.: US7976859B2  Issued: 12/Jul/2011

Title: Implant Filling Material and Method

Applicant/Assignee:

Application No.: 12/861264   Filing Date: 23/Aug/2010

Abstract:

Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.

Priority: US2009-434764 Applic. Date: 2009-05-04; US2006-450644 Applic. Date: 2006-06-09; US2004-839559 Applic. Date: 2004-05-05; US20030533168P Applic. Date: 2003-12-30

Inventor: BEISANG ARTHUR A [US]; ERSEK ROBERT A [US]; BEISANG III ARTHUR A [US]; BEISANG DANIEL J [US]


Patent No.: US7976860B2  Issued: 12/Jul/2011

Title: IMPLANT AND PROCESS FOR ITS PRODUCTION

Applicant/Assignee: JOTEC GMBH

Application No.: 11/849631   Filing Date: 04/Sep/2007

Abstract:

The present invention relates to an implant having a structured material component and having a protein matrix which has a pore structure. The structured material component is moreover at least partly anchored in the protein matrix. The implant also has on at least one its surfaces a protein membrane crosslinked with the protein matrix.

Priority: DE200610042631 Applic. Date: 2006-09-05

Inventor: FISCHER HEIKE [DE]; SCHULZE MONIKA [DE]


Patent No.: US7977369B2  Issued: 12/Jul/2011

Title: Medical Compositions for Intravesical Treatment of Bladder Cancer

Applicant/Assignee: SPECTRUM PHARMACEUTICALS, INC

Application No.: 12/053418   Filing Date: 21/Mar/2008

Abstract:

Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.

Priority: US2006-531535 Applic. Date: 2006-09-13; US2005-096566 Applic. Date: 2005-04-01; US2002-285783 Applic. Date: 2002-11-01; US20010344446P Applic. Date: 2001-11-01

Inventor: NUIJEN BASTIAAN [NL]; PFADENHAUER ERNIE [US]; BEIJNEN JOS H [NL]


Patent No.: US7988986B2  Issued: 02/Aug/2011

Title: Implant Filling Material and Method

Applicant/Assignee:

Application No.: 12/434764   Filing Date: 04/May/2009

Abstract:

Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.

Priority: US2006-450644 Applic. Date: 2006-06-09; US2004-839559 Applic. Date: 2004-05-05; US20030533168P Applic. Date: 2003-12-30

Inventor: BEISANG ARTHUR A [US]; ERSEK ROBERT A [US]; BEISANG III ARTHUR A [US]; BEISANG DANIEL J [US]


Patent No.: US7988991B2  Issued: 02/Aug/2011

Title: Adhesive patch

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: 10/469612   Filing Date: 04/Sep/2003

Abstract:

A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the adhesive base contains an acrylic polymer substantially having no carboxyl and no hydroxyl in molecules thereof, and a rubber-based polymer, so as to achieve sufficiently high skin permeability of the drug and preparation properties. Accordingly, the present invention enables administration of the drug through skin to be implemented with drug administration effect at a sufficiently high level and on a stable basis.

Priority: JP20010063767 Applic. Date: 2001-03-07; WO2002JP02142 Applic. Date: 2002-03-07

Inventor: TATEISHI TETSURO [JP]; TERAHARA TAKAAKI [JP]; HIGO NARUHITO [JP]


Patent No.: US7988999B2  Issued: 02/Aug/2011

Title: Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient

Applicant/Assignee: NYCOMED GMBH

Application No.: 10/433304   Filing Date: 03/Jun/2003

Abstract:

The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.

Priority: EP20000126828 Applic. Date: 2000-12-07; WO2001EP14253 Applic. Date: 2001-12-05

Inventor: DIETRICH RANGO [DE]; LINDER RUDOLF [DE]


Patent No.: US7989000B2  Issued: 02/Aug/2011

Title: Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects

Applicant/Assignee: ORTHOCON, INC

Application No.: 10/941889   Filing Date: 16/Sep/2004

Abstract:

Disclosed are body-implantable, appropriately absorbable, biocompatible, putty-like compositions useful as mechanical hemostatic tamponades for the control of osseous hemorrhage arising from surgical intervention or trauma and for providing an osteoinductive matrix to foster improved bone healing.

Priority: US20030504979P Applic. Date: 2003-09-23

Inventor: KRONENTHAL RICHARD L [US]


Patent No.: US7989003B2  Issued: 02/Aug/2011

Title: METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE

Applicant/Assignee: ZICAM, LLC

Application No.: 12/904749   Filing Date: 14/Oct/2010

Abstract:

A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Priority: US2003-722811 Applic. Date: 2003-11-25; US1999-388816 Applic. Date: 1999-09-01; US1998-145042 Applic. Date: 1998-09-01

Inventor: HENSLEY CHARLES [US]; DAVIDSON ROBERT STEVEN [US]


Patent No.: US7993673B2  Issued: 09/Aug/2011

Title: Swallow tablet comprising paracetamol

Applicant/Assignee: SMITHKLINE BEECHAM LIMITED

Application No.: 10/480960   Filing Date: 03/Dec/2003

Abstract:

A dosage form such as a swallow tablet or a capsule formulation is described comprising paracetamol, low levels of sodium bicarbonate or potassium bicarbonate or mixtures thereof, and at least one pharmaceutically acceptable excipient.

Priority: WO2002EP06046 Applic. Date: 2002-06-03; GB20010014069 Applic. Date: 2001-06-08

Inventor: GRATTAN TIMOTHY JAMES [GB]


Patent No.: US7994111B2  Issued: 09/Aug/2011

Title: LIQUID DETERGENT COMPOSITION COMPRISING AN EXTERNAL STRUCTURING SYSTEM COMPRISING A BACTERIAL CELLULOSE NETWORK

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 12/370714   Filing Date: 13/Feb/2009

Abstract:

A structured liquid detergent composition in the form of a liquid matrix made up of an external structuring system of a bacterial cellulose network

water

and surfactant system including an anionic surfactant

a nonionic surfactant

a cationic surfactant

an ampholytic surfactant

a zwitterionic surfactant

or mixtures thereof, wherein said liquid matrix has a yield stress of from about 0.003 Pa to about 5.0 Pa at about 25 DEG C. and provides suitable particle suspension capabilities and shear thinning characteristics.

Priority: US20080066064P Applic. Date: 2008-02-15

Inventor: CAGGIONI MARCO [US]; ORTIZ RAFAEL [US]; BARNABAS FREDDY ARTHUR [US]; NUNES RAUL VICTORINO [US]; FLOOD JANINE A [US]; COROMINAS FRANCESC [BE]


Patent No.: US7998574B2  Issued: 16/Aug/2011

Title: BIOMEDICAL SENSING METHODS EMPLOYING HYDRO-INSENSITIVE ALTERNATING CURRENT RESPONSIVE COMPOSITES

Applicant/Assignee: FLEXCON COMPANY, INC, FLEXCON COMPANY INC

Application No.: 12/967388   Filing Date: 14/Dec/2010

Abstract:

A method is disclosed of detecting a bioelectrical signal from a subject. The method includes the steps of applying a composite material to a subject wherein the composite material includes a polymeric material and a polar material that is substantially dispersed within the polymeric material

coupling monitoring equipment to the second side of the composite material

permitting the polar material within the polymeric material to respond to the bioelectrical signal within the subject

and detecting a responsive electrical signal from the composite material that is representative of the bioelectrical signal.

The polar material exhibits molecular compatibility with the polymeric material such that the polar material neither blooms to a surface of the polymeric material nor crystallizes within the polymeric material, and the composite material has a first side for contacting the subject and a second side.

Priority: US2010-751558 Applic. Date: 2010-03-31; US2008-123773 Applic. Date: 2008-05-20; US2003-410988 Applic. Date: 2003-04-10; US20020371306P Applic. Date: 2002-04-10

Inventor: SEGALL DANIEL P [US]; HILTON IRIS E [US]; SZYMANSKI MELISSA E [US]; PENNACE JOHN R [US]


Patent No.: US8003637B2  Issued: 23/Aug/2011

Title: STABILIZED ATYPICAL ANTIPSYCHOTIC FORMULATION

Applicant/Assignee: HANDA PHARMACEUTICALS, LLC

Application No.: 13/073873   Filing Date: 28/Mar/2011

Abstract:

A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.

Priority: US2008-205356 Applic. Date: 2008-09-05; US20080083270P Applic. Date: 2008-07-24

Inventor: LIU FANG-YU [US]; SHEN ZHI-QUN [CN]


Patent No.: US8007526B2  Issued: 30/Aug/2011

Title: DIFUNCTIONALIZED AROMATIC COMPOUNDS AND POLYMERS THEREFROM

Applicant/Assignee: BEZWADA BIOMEDICAL, LLC

Application No.: 11/565820   Filing Date: 01/Dec/2006

Abstract:

The present invention relates to compounds of formula I, which are difunctionalized aromatic compounds, and polymers formed from the same. Polymers formed from the di-functionalized aromatics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

Priority: US20050741158P Applic. Date: 2005-12-01

Inventor: BEZWADA RAO S [US]


Patent No.: US8012462B2  Issued: 06/Sep/2011

Title: 1-OXASPIRO (4, 5) DEC-3-ENE DERIVATIVES AS PERFUMING INGREDIENTS

Applicant/Assignee: FIRMENICH SA

Application No.: 12/294591   Filing Date: 17/Apr/2007

Abstract:

The present invention relates to a spiroheterocycle derivative which is a useful perfuming ingredient. Furthermore, the present invention concerns also the compositions or articles containing this compound.

Priority: WO2006IB51410 Applic. Date: 2006-05-04; WO2007IB51369 Applic. Date: 2007-04-17

Inventor: CHAPUIS CHRISTIAN [CH]


Patent No.: US8012505B2  Issued: 06/Sep/2011

Title: Dosage form having a saccharide matrix

Applicant/Assignee: ALK-ABELLO A/S

Application No.: 10/785698   Filing Date: 23/Feb/2004

Abstract:

The present invention provides a non-compressed fast-dispersing solid dosage form suitable for oromucosal administration of a pharmaceutically active substance comprising (a) a first matrix forming agent in the form of maltodextrin having a dextrose equivalent (DE) of between 1 and 20, (b) a second matrix forming agent in the form of sorbitol, and (c) the active substance.

Priority: DK20030000318 Applic. Date: 2003-02-28; US20030465383P Applic. Date: 2003-04-25

Inventor: HOUGHTON CHRISTIAN GAUGUIN [DK]; LUNDEGAARD ANNETTE ROEMMELMAYER [DK]


Patent No.: US8013022B2  Issued: 06/Sep/2011

Title: Stabilized products, process and devices for preparing same

Applicant/Assignee:

Application No.: 11/796451   Filing Date: 27/Apr/2007

Abstract:

Disclosed is a multi-compartment medical device useful in the storage, processing and extended shelf life of perishable products, especially pharmaceutical, food and biological products. Particular biological materials processed according to the present methods are human blood and blood products (RBCs). Also disclosed are processes for preserving food, pharmaceutical and biological products for long-term storage and extended shelf life employing a process that reduces the hydration level of the material to less than native hydration levels of the specific product. The invention further provides stabilized biological products, such as in the form of glassified beads, prepared using a two-phase system according to the described processes that may be rehydrated and prepared for clinical use, and having essentially no loss of biological and/or pharmacological activity.

Priority: US2004-007104 Applic. Date: 2004-12-08; US20030527810P Applic. Date: 2003-12-08; US20040619863P Applic. Date: 2004-10-18

Inventor: DEANGELO JOSEPH [US]; NEEDHAM DAVID [US]; JONES CARROLL [US]


Patent No.: US8017142B2  Issued: 13/Sep/2011

Title: POLYSULFONE BLOCK COPOLYMERS AS DRUG-ELUTING COATING MATERIAL

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/476987   Filing Date: 02/Jun/2009

Abstract:

A polymeric composition comprising a polysulfone polymer and an elastomeric polymer for use as a coating composition for coating an implantable device, such as a DES, and methods of making and using the implantable device are provided.

Priority: US2003-723137 Applic. Date: 2003-11-25

Inventor: CLAUDE CHARLES D [US]; DING NI [US]; YU YEUNG SIU [US]


Patent No.: US8017150B2  Issued: 13/Sep/2011

Title: POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/107389   Filing Date: 22/Apr/2008

Abstract:

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

Priority: US2004-856176 Applic. Date: 2004-05-28; WO2002US32575 Applic. Date: 2002-10-11; WO2002US32594 Applic. Date: 2002-10-11; WO2002US32542 Applic. Date: 2002-10-11; US20030473902P Applic. Date: 2003-05-28; US20020414276P Applic. Date: 2002-09-27; US20020371940P Applic. Date: 2002-04-11

Inventor: YANG ROBERT K [US]; FUISZ RICHARD C [US]; MYERS GARRY L [US]; FUISZ JOSEPH M [US]


Patent No.: US8017160B2  Issued: 13/Sep/2011

Title: Enhancement of magnesium uptake in mammals

Applicant/Assignee:

Application No.: 10/641291   Filing Date: 15/Aug/2003

Abstract:

Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids.

Priority:

Inventor: JAFFE RUSSELL [US]


Patent No.: US8025892B2  Issued: 27/Sep/2011

Title: Cosmetic particulate gel carriers for topically applied active agents

Applicant/Assignee: KOBO PRODUCTS, INC

Application No.: 10/017259   Filing Date: 12/Nov/2001

Abstract:

Gel particles or beads can be prepared by forming a hot aqueous solution of a gelling agent, and discharging the hot gelling agent solution through a discharge orifice into a cold moving stream of hydrophobic liquid so that the gelling agent solution cools rapidly and good quality gel particles coalesce in the cold hydrophobic liquid stream. The cold hydrophobic liquid stream can be contained in a conduit so that the cold hydrophobic liquid stream moves past the discharge orifice and exerts a force on hot solution in the discharge orifice, the force acting to withdraw the hot solution from the discharge orifice. Optionally, the gel particles can be crushable gel beads 10 formed of an agar complex providing cosmetic, pharmaceutical, etc. delivery vehicles for topical delivery of biologically or cosmetically active agents.

Preferred agar beads 10 are complexes of a continuous phase of agar gel 12 in a self-supporting solid or semi-solid form with a restraining polymer 14. Various active agents 16 may be bound to restraining polymer 14, for, example ascorbic acid, lactic acid or papain.

Priority: WO1998IB00977 Applic. Date: 1998-05-01; US1999-431742 Applic. Date: 1999-11-01

Inventor: DELRIEU PASCAL E [FR]; DING LI [FR]


Patent No.: US8025897B2  Issued: 27/Sep/2011

Title: IBUPROFEN COMPOSITION

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 11/423550   Filing Date: 12/Jun/2006

Abstract:

Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives.

Priority: US2003-635069 Applic. Date: 2003-08-05; US1999-305027 Applic. Date: 1999-05-04; US1998-002447 Applic. Date: 1998-01-02

Inventor: BUNICK FRANK J [US]; LIN FENG [US]


Patent No.: US8025899B2  Issued: 27/Sep/2011

Title: Solid pharmaceutical dosage form

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 10/925442   Filing Date: 25/Aug/2004

Abstract:

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 DEG C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Priority: US20030498412P Applic. Date: 2003-08-28

Inventor: BERNDL GUNTHER [DE]; ROSENBERG JOERG [DE]; LIEPOLD BERND [DE]; BREITENBACH JOERG [DE]; REINHOLD ULRICH [DE]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Patent No.: US8025901B2  Issued: 27/Sep/2011

Title: BIFUNCTIONAL-MODIFIED HYDROGELS

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 12/615859   Filing Date: 10/Nov/2009

Abstract:

Disclosed are hydrogels wherein a polymer matrix is modified to contain a bifunctional poly(alkylene glycol) molecule covalently bonded to the polymer matrix. The hydrogels can be cross-linked using, for example, glutaraldehyde. The hydrogels may also be crosslinked via an interpenetrating network of a photopolymerizable acrylates. The hydrogels may also be modified to have pharmacologically-active agents covalently bonded to the poly(alkylene glycol) molecules or entrained within the hydrogel. Living cells may also be entrained within the hydrogels.

Priority: US2002-128198 Applic. Date: 2002-04-23; US20010285782P Applic. Date: 2001-04-23

Inventor: KAO WEIYUAN JOHN [US]; LI JING [US]; LOK DAVID [US]; GUNDLOORI RATHNA [IN]


Patent No.: US8026196B2  Issued: 27/Sep/2011

Title: DELAYED-EFFECT AGRONOMIC TREATMENT AGENT, IN PARTICULAR FOR SEED GERMINATION AND PLANT DEVELOPMENT

Applicant/Assignee: CLAUSE TEZIER, CLAUSE

Application No.: 12/282136   Filing Date: 08/Mar/2006

Abstract:

Agent for the agronomic treatment of a living plant supported by a moist substrate, for example a soil, wherein said agent is in the solid and divided state, and comprises solid particles containing at least one active entity for the agronomic treatment, characterized in that each particle comprises:

-a nucleus consisting of a grain of a solid material which is inert with respect to the substrate, comprising an inner developed surface area which is greater than its apparent surface area and, as a result, suitable for adsorption and/or absorption, -the active entity for agronomic treatment, absorbed into the grain and/or adsorbed at the surface of said grain, -a membrane encapsulating the nucleus comprising the active entity, consisting of at least one hydrophilic polymer which is permeable to the outside with respect to the active entity, when it is in direct or indirect contact with the moist substrate.

Priority: WO2006FR00517 Applic. Date: 2006-03-08

Inventor: GAUDILLAT MICHEL [FR]


Patent No.: US8034379B2  Issued: 11/Oct/2011

Title: Ion-strength independent sustained release pharmaceutical formulation

Applicant/Assignee: SOLVAY PHARMACEUTICALS B.V

Application No.: 10/381714   Filing Date: 28/Mar/2003

Abstract:

The present invention is related to an optionally coated pharmaceutical hydrophilic gel forming matrix formulation comprising one or more active substances and having a prolonged release of said one or more active substances upon exposure to gastrointestinal fluids, characterized in that said release is substantially ion-strength independent. The invention is further related to a method of preparing this formulation which can be used in the administration of active substances for the treatment of a large number of disorders.

Priority: EP20000203381 Applic. Date: 2000-09-29; WO2001EP11285 Applic. Date: 2001-09-28; NL20001016295 Applic. Date: 2000-09-29

Inventor: GORISSEN HENRICUS R M [NL]; FRIJLINK HENDERIK W [NL]


Patent No.: US8039010B2  Issued: 18/Oct/2011

Title: SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER

Applicant/Assignee: ALLERGAN, INC

Application No.: 11/556503   Filing Date: 03/Nov/2006

Abstract:

A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.

Priority:

Inventor: TROGDEN JOHN T [US]; LYONS ROBERT T [US]


Patent No.: US8043627B2  Issued: 25/Oct/2011

Title: OSTEOGENIC COMPOSITE MATRIX, METHOD FOR THE PRODUCTION THEREOF AND IMPLANT AND SCAFFOLD FOR TISSUE ENGINEERING PROVIDED WITH A COATING FORMED BY SAID OSTEOGENIC COMPOSITE MATRIX

Applicant/Assignee: NEXILIS AG

Application No.: 12/572884   Filing Date: 02/Oct/2009

Abstract:

The invention relates to an osteogenic composite matrix consisting of collagen and non-collagen components of an extracellular matrix (ECM-components), to a method for producing said matrix, to a method for producing an implant or a scaffold for tissue engineering which is provided with a coating formed by said osteogenic composite matrix and is used for stimulating and accelerating a hard tissue formation such as, for example. The implant osseointegration in bones. The inventive osteogenic composite matrix comprises a collagen and at least one non-collagen ECM component or the derivatives thereof, wherein the collagen component consists of non-crosslinked collagen fibers produced by fibrillogenesis and the non-collagen ECM component or the derivatives thereof are integrated into said collagen fibers.

Priority: DE200410018959 Applic. Date: 2004-04-15; US2007-578607 Applic. Date: 2007-05-30; WO2005DE00728 Applic. Date: 2005-04-15

Inventor: SCHARNWEBER DIETER [DE]; WORCH HARTMUT [DE]; BIERBAUM SUSANNE [DE]


Patent No.: US8052984B2  Issued: 08/Nov/2011

Title: Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages

Applicant/Assignee: BIOPHILE CORPORATION, LTD

Application No.: 12/012647   Filing Date: 05/Feb/2008

Abstract:

The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment

the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle.

The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species through the bead structure, thus stabilizes the positively charged active ingredient inside the bead by impeding the interaction of the positively charged active ingredient and the catalytic species, and thereby extending the shelf life of the positively charged active ingredient.

Priority: US20070899433P Applic. Date: 2007-02-05

Inventor: SUVANPRAKORN PICHIT [TH]; VAYUMHASUWAN PANIDA [TH]; ZAIAS NARDO [US]


Patent No.: US8052990B2  Issued: 08/Nov/2011

Title: Biocompatible crosslinked gel

Applicant/Assignee: ANTEIS S.A

Application No.: 10/588186   Filing Date: 31/Jan/2005

Abstract:

The invention relates to a method for producing a biocompatible crosslinked gel consisting in crosslinking a determined quantity of at least one type of liquid biocompatible polymer by adding a quantity of crosslinking agent, in carrying out a crosslinking reaction, in adding an additional quantity of liquid polymer whose molecular mass is greater than 500,000 Da, in solving the reaction mixture in such a way that the total concentration of the liquid polymer is reduced, in crosslinking and in stopping the crosslinking reaction by removing the crosslinking agent. The inventive gel and the use thereof are also disclosed.

Priority: FR20040000987 Applic. Date: 2004-02-03; WO2005FR00197 Applic. Date: 2005-01-31

Inventor: HERMITTE LAURENCE [FR]; BENOIT OLIVIER [FR]


Patent No.: US8052997B2  Issued: 08/Nov/2011

Title: ANTI-BACTERIAL COMPOSITION AND METHOD FOR PRODUCING THE SAME

Applicant/Assignee: CHUNG-SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY ARMAMENTS BUREAU, MINISTRY OF NATIONAL DEFENSE

Application No.: 12/426195   Filing Date: 17/Apr/2009

Abstract:

The invention discloses an anti-bacterial composition and method for producing the same. The anti-bacterial composition of the invention includes an organic siloxane material which comprises an amino group, and a plurality of silver atoms. Particularly, the organic siloxane material has a meshed structure, and the plurality of silver atoms are bonded to the amino group and are well dispersed in the meshed structure.

Priority:

Inventor: YANG CHENG-CHIEN [TW]; WU KUO-HUI [TW]; GU WANG-TSAI [TW]; CHEN CHIN-YIH [TW]; YANG FU-CHU [TW]


Patent No.: US8053467B2  Issued: 08/Nov/2011

Title: Flavor improving agent, and food and drink containing the same

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: 12/311568   Filing Date: 05/Oct/2007

Abstract:

The present invention provides a novel flavor improving agent capable of sufficiently enhancing or alleviating the flavor sensed in oral cavity

for example, enhancing and improving the thickness in taste or the like to provide depth and profoundness to the flavor, and also improving the sense of volume or the sharpness of aftertaste. The present invention also provides a food/drink, a pharmaceutical product and an oral care product having a good taste which can fulfill the recent high-level demand for taste.

Priority: JP20060275847 Applic. Date: 2006-10-06; WO2007JP70028 Applic. Date: 2007-10-05

Inventor: TERADA IKUO [JP]; TAKEDA TOSHIHIRO [JP]; KOBAYASHI TSUYOSHI [JP]; HIRAMOTO TADAHIRO [JP]


Patent No.: US8057818B2  Issued: 15/Nov/2011

Title: Methods of making expandable foam-like biomaterials

Applicant/Assignee: CRYOLIFE, INC

Application No.: 11/042181   Filing Date: 26/Jan/2005

Abstract:

Liquid, injectable, aqueous solutions are transformed in situ to an expandable foam-like, space filling, and adherent biomaterial. Preferably, the foam-like biomaterial is the reaction product of a two-part liquid system to achieve the in situ formation thereof. The liquid system is generally comprised of a protein solution and a cross linker solution which may either be premixed and then applied to a site in need of the biomaterial, or simultaneously mixed and delivered through an in-line mixing/dispensing tip directly to the site. In especially preferred embodiments, an expandable foam-like biomaterial includes the reaction product of human or animal-derived protein material and a di- or polyaldehyde in the presence of a bicarbonate and an acidic titrant amounts sufficient to impart a cellular foam structure to the material.

Priority: US2001-986124 Applic. Date: 2001-11-07; US20000246063P Applic. Date: 2000-11-07

Inventor: YUEKSEL K UMIT [US]; BIRD ANA T [US]; BLACK KIRBY S [US]


Patent No.: US8062667B2  Issued: 22/Nov/2011

Title: Modified release formulations containing drug-ion exchange resin complexes

Applicant/Assignee: TRIS PHARMA, INC

Application No.: 11/724966   Filing Date: 15/Mar/2007

Abstract:

A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.

Priority: US20060783181P Applic. Date: 2006-03-16

Inventor: MEHTA KETAN [US]; TU YU-HSING [US]


Patent No.: US8067020B2  Issued: 29/Nov/2011

Title: SUSTAINED RELEASE FORMULATION

Applicant/Assignee: GENETECH, INC

Application No.: 11/954608   Filing Date: 12/Dec/2007

Abstract:

A composition comprises a protein, a polyol, and a metal. The protein is stabilized by the polyol and the metal, and is protected from denaturing when in contact with an organic solvent. The polyol may be a hydrocarbon containing two or more hydroxyl groups (-OH) bonded to carbon. The metal may be divalent.

Priority: US2002-176961 Applic. Date: 2002-06-21; US20010300275P Applic. Date: 2001-06-21

Inventor: OKUMU FRANKLIN [US]; CLELAND JEFFREY L [US]


Patent No.: US8067028B2  Issued: 29/Nov/2011

Title: DRUG DELIVERY DEVICE

Applicant/Assignee: CONFLUENT SURGICAL, INC, CONFLUENT SURGICAL INC

Application No.: 12/165972   Filing Date: 01/Jul/2008

Abstract:

Drug delivery devices are provided herein including crosslinked polymeric compositions. The devices may, in embodiments, possess at least two drug release profiles, in embodiments at least three drug release profiles.

Priority: US20070964488P Applic. Date: 2007-08-13

Inventor: BENNETT STEVEN L [US]


Patent No.: US8067031B2  Issued: 29/Nov/2011

Title: Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Applicant/Assignee: ANGIODEVICE INTERNATIONAL GMBH

Application No.: 11/118088   Filing Date: 28/Apr/2005

Abstract:

Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

Priority: US20040566569P Applic. Date: 2004-04-28

Inventor: DANILOFF GEORGE Y [US]; SEHL LOUIS C [US]; TROLLSAS OLOF MIKAEL [US]; SCHROEDER JACQUELINE [US]; GRAVETT DAVID M [CA]; TOLEIKIS PHILIP M [CA]


Patent No.: US8067469B2  Issued: 29/Nov/2011

Title: System for trapping flying insects with attractant lures

Applicant/Assignee: AMERICAN BIOPHYSICS CORPORATION, WOODSTREAM CORPORATION

Application No.: 10/864284   Filing Date: 08/Jun/2004

Abstract:

The present application discloses a system for trapping flying insects, a first chemical lure such as lactic acid, a salt of lactic acid, or combinations thereof, and a second chemical lure comprising a source of ammonia. The lures may be employed in particular geometric shapes contained in specifically designed housing to ensure an effective release rate over extended periods of time.

Priority: US2003-431586 Applic. Date: 2003-05-08; US20020378369P Applic. Date: 2002-05-08

Inventor: DURAND EMMA A [US]; CAO MIAO-YONG [US]; LIU CUIXIA [US]; DUNNE RICHARD B [US]


Patent No.: US8071124B2  Issued: 06/Dec/2011

Title: Methods of using expandable foam-like biomaterials

Applicant/Assignee: CRYOLIFE, INC

Application No.: 11/042180   Filing Date: 26/Jan/2005

Abstract:

Liquid, injectable, aqueous solutions are transformed in situ to an expandable foam-like, space filling, and adherent biomaterial. Preferably, the foam-like biomaterial is the reaction product of a two-part liquid system to achieve the in situ formation thereof. The liquid system is generally comprised of a protein solution and a cross linker solution which may either be premixed and then applied to a site in need of the biomaterial, or simultaneously mixed and delivered through an in-line mixing/dispensing tip directly to the site. In especially preferred embodiments, an expandable foam-like biomaterial includes the reaction product of human or animal-derived protein material and a di- or polyaldehyde in the presence of a bicarbonate and an acidic titrant amounts sufficient to impart a cellular foam structure to the material.

Priority: US2001-986124 Applic. Date: 2001-11-07; US20000246063P Applic. Date: 2000-11-07

Inventor: YUKSEL K UMIT [US]; BIRD ANA T [US]; BLACK KIRBY S [US]


Patent No.: US8071131B2  Issued: 06/Dec/2011

Title: Mineralizing Composite Materials for Restoring Teeth

Applicant/Assignee: DENTIGENIX INC, IVOCLAR VIVADENT, INC

Application No.: 11/572013   Filing Date: 11/Jul/2005

Abstract:

Compositions and methods useful in restorative dentistry are disclosed. Compositions of the present invention include a peptide, and a polymer matrix. The peptide is one capable of reacting with a source of mineralizing ions to initiate deposition of hydroxyapatite crystals within the polymer matrix. Compositions of the present invention are uniquely capable of sealing a junction between a dental restorative material and adjacent native tooth tissue.

Priority: US20040589214P Applic. Date: 2004-07-15; WO2005US24409 Applic. Date: 2005-07-11

Inventor: RUTHERFORD BRUCE [US]


Patent No.: US8075562B2  Issued: 13/Dec/2011

Title: CONTROLLED RELEASE OF BIOPHARMACEUTICAL GROWTH FACTORS FROM HYDROXYAPATITE COATING ON BIORESORBABLE INTERFERENCE SCREWS USED IN CRUCIATE LIGAMENT RECONSTRUCTION SURGERY

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 12/145672   Filing Date: 25/Jun/2008

Abstract:

Controlled release of biopharmaceutical growth factors from a hydroxyapatite coating on a bioresorbable interference screw used in cruciate ligament reconstruction surgery on a human. Biologically active scaffolds, such as interference bone screws used for ligament fixation, made by growing calcium phosphate-based hydroxyapatite coatings on bioresorbable poly([alpha]-hydroxy ester) scaffolds that provide controlled mineral dissolution and controlled release of bone morphogenetic protein-2. The biologically active scaffold provides improved bioavailability of BMP-2 growth factor that in turn provides enhanced graft-bone healing in the tibial bone tunnel. The coating method uses surface hydrolysis and modified simulated body fluid incubation which does not require solvent or heat and is conducted at room temperature.

Priority: US20070937460P Applic. Date: 2007-06-25

Inventor: MURPHY WILLIAM L [US]; LEE JAE-SAM [US]; MARKEL MARK D [US]; GRAF BEN K [US]


Patent No.: US8075907B2  Issued: 13/Dec/2011

Title: POLYMETHYLMETHACRYLATE REVISION BONE CEMENT

Applicant/Assignee: HERAEUS KULZER GMBH

Application No.: 12/017499   Filing Date: 22/Jan/2008

Abstract:

The invention relates to a PMMA revision bone cement having powder and liquid component, in which the powder component contains two or more granular antibiotics whose grain size distribution is equal in that the main screening fraction each of the individual antibiotics is in the same grain size range, in particular in the range of 100-250 [mu]m or 150-250 [mu]m.

Priority: DE200710004968 Applic. Date: 2007-01-26

Inventor: KUEHN KLAUS-DIETER [DE]; VOGT SEBASTIAN [DE]; BUECHNER HUBERT [DE]


Patent No.: US8075912B2  Issued: 13/Dec/2011

Title: Autodestructive Transdermal Therapeutic System

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/301244   Filing Date: 22/May/2007

Abstract:

The invention relates to a transdermal therapeutic system (TTS), preferably in the form of a transdermal plaster, that contains an active substance and an agent which can destroy the active substance. The TTS further includes a means of bringing the active substance, e.g. buprenorphine, and the agent, e.g. potassium permanganate, into contact when the TTS is removed from the skin of the patient, thereby causing the active substance to be destroyed.

Priority: DE200610025282 Applic. Date: 2006-05-31; WO2007EP04516 Applic. Date: 2007-05-22

Inventor: HOFFMANN HANS-RAINER [DE]; HILLE THOMAS [DE]


Patent No.: US8075915B2  Issued: 13/Dec/2011

Title: Composition and method of transmitting ultrasonic and electrical impulses using a physiologically compatible conductive agent

Applicant/Assignee:

Application No.: 11/237438   Filing Date: 28/Sep/2005

Abstract:

The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %

(b) an unbranched or branched alcohol having from 1 to about 4 carbon atoms present in an amount up to about 70 wt. %

and (c) the balance water. The present invention also provides a physiologically compatible conductive agent comprising long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %

(b) a surface tension reducing amount of a surfactant

and (c) the balance water. The present invention further provides methods for transmitting electrical or ultrasonic impulses to a surface in contact with a transducer with a conductivity gap by applying to the conductivity gap the novel physiologically compatible conductive agents. The present invention also provides methods for preparing the physiologically compatible conductive agents of the present invention.

Priority:

Inventor: BUCHALTER GILBERT [US]


Patent No.: US8076139B1  Issued: 13/Dec/2011

Title: Processes and compositions for transfecting Chinese hamster ovary (CHO) cells

Applicant/Assignee: LEINCO TECHNOLOGIES, INC

Application No.: 11/750401   Filing Date: 18/May/2007

Abstract:

The present invention generally relates to processes and compositions for the transfection of Chinese hamster ovary (CHO) cells. More specifically, the present invention relates to processes for the transfection of CHO cells suspended in an aqueous medium using a transfection composition containing nucleic acid and linear polyethyleneimine.

Priority: US20060846664P Applic. Date: 2006-09-22; US20060843186P Applic. Date: 2006-09-08; US20060802914P Applic. Date: 2006-05-24; US20060802041P Applic. Date: 2006-05-19

Inventor: HAMM SARAH E [US]; LEINERT WILLIAM P [US]


Patent No.: US8080260B2  Issued: 20/Dec/2011

Title: Molecular enhancement of extracellular matrix and methods of use

Applicant/Assignee: THE CLEVELAND CLINIC FOUNDATION

Application No.: 12/378296   Filing Date: 13/Feb/2009

Abstract:

A composition comprising a human- or animal-derived extracellular matrix and a macromolecular network which is prepared ex vivo is provided that is useful in the repair of a tissue injury, particularly in repair of tears or gaps between a tendon and a bone, such as in a rotator cuff tear. In an embodiment, the composition comprises a human- or animal-derived extracellular matrix having impregnated therein a macromolecular network of hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages, so that the cross-linked network is interlocked within the extracellular matrix. The resulting HA-incorporated extracellular matrix can be supplied in the form of a patch to reinforce a tissue repair or cover a tissue defect.

Priority: US20080065527P Applic. Date: 2008-02-13

Inventor: DERWIN KATHLEEN ANNE [US]; IANNOTTI JOSEPH PATRICK [US]; CHIN LIKANG [US]; CALABRO ANTHONY [US]


Patent No.: US8084482B2  Issued: 27/Dec/2011

Title: COMPOSITIONS AND KITS COMPRISING A FUNGICIDAL TRIAZOLE AND AN ALKOXYLATED ALCOHOL, AND THEIR USES

Applicant/Assignee: BASF SE

Application No.: 12/517915   Filing Date: 06/Dec/2007

Abstract:

The present invention relates to compositions comprising (a1) a fungicidal triazole

and (b1) ethoxylated 2-propylheptanol having a mole average degree of ethoxylation from 7.5 to 8.5, to kits comprising the triazole and alcohol alkoxylate in separate containers, as well as to their uses in the agricultural field. The present invention also relates to use of ethoxylated 2-propylheptanol having a degree of ethoxylation from 7.5 to 8.5 as adjuvant and surfactant safener.

Priority: US20060869030P Applic. Date: 2006-12-07; WO2007EP63417 Applic. Date: 2007-12-06

Inventor: BARDINELLI TED R [US]; FINCH CHARLES W [US]


Patent No.: US8084506B2  Issued: 27/Dec/2011

Title: SEBUM ABSORPTION COMPOSITIONS

Applicant/Assignee: MARY KAY INC

Application No.: 12/408182   Filing Date: 20/Mar/2009

Abstract:

Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient

and (b) 20% to 99% by weight of the composition of a volatile solvent.

Priority: US20080039337P Applic. Date: 2008-03-25

Inventor: ZHAO WANLI [US]


Patent No.: US8084513B2  Issued: 27/Dec/2011

Title: Implant Filling Material and Method

Applicant/Assignee:

Application No.: 12/463526   Filing Date: 11/May/2009

Abstract:

Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.

Priority: US2006-450644 Applic. Date: 2006-06-09; US2004-839559 Applic. Date: 2004-05-05; US20030533168P Applic. Date: 2003-12-30

Inventor: BEISANG ARTHUR A [US]; ERSEK ROBERT A [US]; BEISANG III ARTHUR A [US]; BEISANG DANIEL J [US]